To analyze the impact of federal regulations on hospitals providing gender-affirming treatments for minors.
Key Findings:
At least nine hospitals have stopped providing gender-affirming hormones and puberty blockers since the start of the year due to proposed federal regulations.
More than 40 hospitals nationwide have paused or ceased gender-affirming care since the beginning of 2023.
Interpretation:
Hospitals are preemptively complying with federal regulations to avoid penalties, despite ongoing legal challenges to these rules.
Limitations:
The proposed CMS rules are not yet finalized, leading to uncertainty in hospital responses.
The analysis does not provide specific names of all hospitals affected by the regulations, which limits understanding of the scope.
Conclusion:
The increasing cessation of gender-affirming treatments for minors reflects a significant shift in healthcare access due to federal regulations, impacting young transgender patients' ability to receive necessary care.
